Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How would you treat a patient with a post prostatectomy biochemical and pelvic nodal recurrence with a BLM mutation?
Related Questions
How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?
How do you manage prostate cancer in patients that cannot swallow pills?
How long would you delay prostate radiation following use of a paclitaxel-eluting balloon dilator (optilume) for management of a recurrent urethral stricture after TURP?
How do you approach radiotherapy planning when there is no identifiable prostate tissue after HIFU or TURP?
Do you ever dose escalate radiotherapy to the primary in low volume metastatic prostate cancer?
How would you manage an aortocaval nodal recurrence of prostate cancer in a patient who previously received salvage radiation to the fossa and pelvic nodes?
Given the different rates of testosterone recovery, do you alter the duration of ADT when using Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation?
How would you manage incidentally-found prostate cancer on TURP?
What is your preferred dose to gross lymph nodes when treating non-metastatic high-risk prostate cancer?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
